Market Cap 80.18B
Revenue (ttm) 40.10B
Net Income (ttm) 3.29B
EPS (ttm) N/A
PE Ratio 9.59
Forward PE 9.23
Profit Margin 8.21%
Debt to Equity Ratio 1.30
Volume 3,720,508
Avg Vol 5,131,090
Day's Range N/A - N/A
Shares Out 2.07B
Stochastic %K 20%
Beta 0.58
Analysts Sell
Price Target $41.74

Latest News on GSK

US FDA approves GSK's urinary tract infection drug

Mar 25, 2025, 12:00 PM EDT - 8 days ago

US FDA approves GSK's urinary tract infection drug


GSK abandons diversity targets following Trump pressure

Feb 27, 2025, 11:15 AM EST - 4 weeks ago

GSK abandons diversity targets following Trump pressure


Canada purchases 500,000 doses of GSK's vaccine for bird flu

Feb 19, 2025, 12:13 PM EST - 6 weeks ago

Canada purchases 500,000 doses of GSK's vaccine for bird flu


GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'

Feb 18, 2025, 2:21 AM EST - 6 weeks ago

GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'


US FDA approves GSK's combo meningococcal vaccine

Feb 14, 2025, 9:37 PM EST - 6 weeks ago

US FDA approves GSK's combo meningococcal vaccine


Hedge Fund Citadel takes short position in GSK, FT reports

Feb 14, 2025, 12:20 PM EST - 6 weeks ago

Hedge Fund Citadel takes short position in GSK, FT reports


Law Offices of Frank R. Cruz Encourages GSK plc.

Feb 11, 2025, 12:10 PM EST - 7 weeks ago

Law Offices of Frank R. Cruz Encourages GSK plc.


Law Offices of Howard G. Smith Encourages GSK plc.

Feb 7, 2025, 12:00 PM EST - 7 weeks ago

Law Offices of Howard G. Smith Encourages GSK plc.


GSK Reported Strong Earnings, So I Reiterate My Strong Buy

Feb 6, 2025, 8:00 AM EST - 7 weeks ago

GSK Reported Strong Earnings, So I Reiterate My Strong Buy


GSK plc (GSK) Q4 2024 Earnings Call Transcript

Feb 5, 2025, 11:52 AM EST - 2 months ago

GSK plc (GSK) Q4 2024 Earnings Call Transcript